By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Plethora Solutions Holdings 



London  England    United Kingdom
Phone: n/a Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation 7/29/2009 9:44:44 AM
Plethora Solutions Holdings Sells Lead Drug Rights, Cuts Debt by 90% 5/26/2009 7:30:01 AM
Sciele Pharma, Inc. (SCRX) And Plethora Solutions Holdings Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation 4/28/2009 9:26:58 AM
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Completion of Patient Recruitment for Global Phase III Trial of PSD502 for Premature Ejaculation 2/18/2009 10:12:20 AM
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Final Analysis of PSD502 for Premature Ejaculation; All Primary and Secondary Endpoints Met in Phase III Pivotal Trial 12/8/2008 12:39:55 PM
Plethora Solutions Holdings Release: New Study Confirms the Role of ErecAid(R) as Supplemental First Line Treatment for Erectile Dysfunction 11/18/2008 8:17:28 AM
Sciele Pharma, Inc. (SCRX) Announces That Plethora Solutions Holdings Has Completed European Phase III Trial of PSD502 for Premature Ejaculation 10/1/2008 9:14:11 AM
Plethora Solutions Holdings and Paul Capital Healthcare Sign a $25M Revenue Interest Financing Agreement 4/1/2008 7:11:29 AM
Sciele Pharma, Inc. (SCRX) Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation; Sciele to Purchase $7 Million Stake in Plethora 5/24/2007 9:21:19 AM
Inyx, Inc. Signs Deal With Plethora Solutions Holdings To Produce Novel HFA Aerosol Indicated For The Treatment Of Premature Ejaculation For Clinical Trial In The United States 11/2/2006 4:11:27 PM
12
//-->